These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 12430875)
1. Growth mechanism of human myeloma cells by interleukin-6. Kawano MM; Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X Int J Hematol; 2002 Aug; 76 Suppl 1():329-33. PubMed ID: 12430875 [TBL] [Abstract][Full Text] [Related]
2. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Ishikawa H; Mahmoud MS; Fujii R; Abroun S; Kawano MM Leuk Lymphoma; 2000 Sep; 39(1-2):51-5. PubMed ID: 10975383 [TBL] [Abstract][Full Text] [Related]
3. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Kawano MM Leuk Lymphoma; 2003 Sep; 44(9):1477-81. PubMed ID: 14565647 [TBL] [Abstract][Full Text] [Related]
5. The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells. Tsuyama N; Ishikawa H; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Obata M; Taniguchi O; Kawano MM Hematology; 2003 Dec; 8(6):409-11. PubMed ID: 14668037 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules. Ishikawa H; Tsuyama N; Kawano MM Int J Hematol; 2003 Aug; 78(2):95-105. PubMed ID: 12953802 [TBL] [Abstract][Full Text] [Related]
7. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Otsuyama K; Asaoku H; Kawano MM Int J Hematol; 2006 Jan; 83(1):39-43. PubMed ID: 16443550 [TBL] [Abstract][Full Text] [Related]
8. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Taniguchi O; Kawano MM Blood; 2002 Mar; 99(6):2172-8. PubMed ID: 11877294 [TBL] [Abstract][Full Text] [Related]
9. Biological significance of heterogeneity in human myeloma cells. Ishikawa H; Kawano MM Int J Hematol; 1998 Dec; 68(4):363-70. PubMed ID: 9885436 [TBL] [Abstract][Full Text] [Related]
10. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Mahmoud MS; Ishikawa H; Fujii R; Kawano MM Blood; 1998 Nov; 92(10):3887-97. PubMed ID: 9808582 [TBL] [Abstract][Full Text] [Related]
11. The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells. Zhou Q; Yao Y; Ericson SG Int J Hematol; 2004 Jan; 79(1):63-73. PubMed ID: 14979481 [TBL] [Abstract][Full Text] [Related]
12. Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas. Ishikawa H; Tsuyama N; Obata M; M Kawano M J Clin Exp Hematop; 2006 Nov; 46(2):55-66. PubMed ID: 17142955 [TBL] [Abstract][Full Text] [Related]
13. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis. Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 gene expression is preferentially restricted in VLA-5-MPC-1- immature but not in VLA-5+MPC-1+ mature myeloma cells. Mihara K Int J Hematol; 1996 Apr; 63(3):215-26. PubMed ID: 8936335 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629 [TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively. Kawano MM; Mahmoud MS; Ishikawa H Br J Haematol; 1997 Oct; 99(1):131-8. PubMed ID: 9359513 [TBL] [Abstract][Full Text] [Related]
17. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Okura M; Ida N; Yamauchi T Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194 [TBL] [Abstract][Full Text] [Related]
18. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells. Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967 [TBL] [Abstract][Full Text] [Related]
19. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Collette M; Descamps G; Pellat-Deceunynck C; Bataille R; Amiot M Eur Cytokine Netw; 2007 Sep; 18(3):120-6. PubMed ID: 17823079 [TBL] [Abstract][Full Text] [Related]
20. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]